Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 20/20 | 1.00 |
| ▸ | TTK | P33981 | 10/20 | 1.00 |
| ▸ | AURKA | O14965 | 1/20 | 0.84 |
| ▸ | CSF1R | P07333 | 2/20 | 0.81 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.81 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.81 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.81 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.81 |
| ▸ | MTOR | P42345 | 1/20 | 0.81 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.81 |
| ▸ | ATM | Q13315 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20358252 | 1.00 | PRKDC (1.00) | PRKDCTTKAURKACSF1RPIK3CD | |
| SCHEMBL20358847 | 1.00 | PRKDC (1.00) | PRKDCTTKAURKACSF1RPIK3CD | |
| SCHEMBL29770931 | 1.00 | PRKDC (1.00) | PRKDCTTKAURKACSF1RPIK3CD | |
| SCHEMBL23625297 | 0.95 | PRKDC (0.90) | PRKDCTTKAURKACSF1RPIK3CD | |
| SCHEMBL23625296 | 0.95 | PRKDC (0.90) | PRKDCTTKAURKACSF1RPIK3CD | |
| SCHEMBL23625300 | 0.95 | PRKDC (0.90) | PRKDCTTKAURKACSF1RPIK3CD | |
| SCHEMBL23625483 | 0.95 | PRKDC (0.90) | PRKDCTTKAURKACSF1RPIK3CD | |
| SCHEMBL23611088 | 0.95 | PRKDC (0.90) | PRKDCTTKAURKACSF1RPIK3CD | |
| SCHEMBL23625322 | 0.92 | PRKDC (0.85) | PRKDCTTKAURKACSF1RPIK3CD | |
| SCHEMBL20299415 | 0.91 | PRKDC (1.00) | PRKDCTTKAURKACSF1RPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136340-B2 | Amino-triazolopyridine compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2021-10-05 | — | — | US | claimed |
| EP-3558997-B1 | AMINO-TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2021-01-27 | — | — | EP | claimed |
| US-20200048281-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2020-02-13 | — | — | US | claimed |
| US-10407446-B2 | Amino-triazolopyridine compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2019-09-10 | — | — | US | claimed |
| US-20180194782-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2018-07-12 | — | — | US | claimed |
| US-20240124492-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2024-04-18 | — | — | US | disclosed |
| US-11746118-B2 | Amino-triazolopyridine compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2023-09-05 | — | — | US | disclosed |
| US-11746118-B2 | Amino-triazolopyridine compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2023-09-05 | — | — | US | disclosed |
| US-11746118-B2 | Amino-triazolopyridine compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2023-09-05 | — | — | US | disclosed |
| WO-2021260583-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND DNA-PK INHIBITOR | ASTRAZENECA UK LIMITED (GB) | 2021-12-30 | — | — | WO | disclosed |
| US-11136340-B2 | Amino-triazolopyridine compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2021-10-05 | — | — | US | disclosed |
| US-11136340-B2 | Amino-triazolopyridine compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2021-10-05 | — | — | US | disclosed |
| US-20200048281-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2020-02-13 | — | — | US | disclosed |
| US-20200048281-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2020-02-13 | — | — | US | disclosed |
| US-10407446-B2 | Amino-triazolopyridine compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2019-09-10 | — | — | US | disclosed |
| US-10407446-B2 | Amino-triazolopyridine compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2019-09-10 | — | — | US | disclosed |
| US-20180194782-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20180194782-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20180194782-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| WO-2018114999-A1 | AMINO-TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124492-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | DCK, TYMP, DPYD | PRKDC 20/4885TTK 185/4885AURKA 392/4885 |
| US-11136340-B2 | Amino-triazolopyridine compounds and their use in treating cancer | DCK, TYMP, DPYD | PRKDC 20/4885TTK 185/4885AURKA 392/4885 |
| US-20180194782-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | DCK, TYMP, DPYD | PRKDC 20/4885TTK 185/4885AURKA 392/4885 |
| US-11746118-B2 | Amino-triazolopyridine compounds and their use in treating cancer | DCK, TYMP, DPYD | PRKDC 20/4885TTK 185/4885AURKA 392/4885 |
| US-20200048281-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | DCK, TYMP, DPYD | PRKDC 20/4885TTK 185/4885AURKA 392/4885 |
| US-10407446-B2 | Amino-triazolopyridine compounds and their use in treating cancer | DCK, TYMP, DPYD | PRKDC 20/4885TTK 185/4885AURKA 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.